KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Charles River Laboratories International (CRL) Revenue (2016 - 2025)

Charles River Laboratories International (CRL) has 17 years of Revenue data on record, last reported at $994.2 million in Q4 2025.

  • For Q4 2025, Revenue fell 0.83% year-over-year to $994.2 million; the TTM value through Dec 2025 reached $4.0 billion, down 0.85%, while the annual FY2025 figure was $4.0 billion, 0.85% down from the prior year.
  • Revenue reached $994.2 million in Q4 2025 per CRL's latest filing, down from $1.0 billion in the prior quarter.
  • Across five years, Revenue topped out at $1.1 billion in Q4 2022 and bottomed at $824.6 million in Q1 2021.
  • Average Revenue over 5 years is $985.6 million, with a median of $1.0 billion recorded in 2024.
  • Peak YoY movement for Revenue: surged 33.99% in 2021, then decreased 7.85% in 2023.
  • A 5-year view of Revenue shows it stood at $905.0 million in 2021, then grew by 21.52% to $1.1 billion in 2022, then fell by 7.85% to $1.0 billion in 2023, then dropped by 1.08% to $1.0 billion in 2024, then dropped by 0.83% to $994.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Revenue were $994.2 million in Q4 2025, $1.0 billion in Q3 2025, and $1.0 billion in Q2 2025.